Targeting immune checkpoints such as programmed cell death protein 1 (PD1) and programmed cell death 1 ligand 1 (PD-L1) yields notable benefits in the treatment of most types of cancer by blocking immune-inhibitory signaling and enabling patients to produce an effective anti-cancer immune-response [24]. This evidence concerns the gene PDCD1 and cancer.